<DOC>
	<DOCNO>NCT00255814</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . PURPOSE : This phase I trial study side effect best dose radiation therapy treat patient liver metastasis .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Liver Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose high dose per fraction , highly conformal radiotherapy patient liver metastasis . Secondary - Determine failure pattern survival patient treat regimen . - Correlate dose-volume characteristic possible toxic effect regimen patient . - Determine local control rate within irradiate field patient treat regimen . OUTLINE : This multicenter , dose-escalation study . Patients undergo highly conformal radiotherapy ( HCR ) liver daily , 5 day week , 2 week . Cohorts 6 patient receive escalate dos HCR maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 18 patient accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Histologically confirm nonlymphoma liver metastases New radiographic liver lesion consistent metastasis patient know , histologically proven nonlymphoma cancer AND previously negative CT scan , MRI , PET/CT scan liver No 5 measurable lesion contrastenhanced liver CT scan , MRI , PET/CT scan Liver metastases ≤ 8 cm Medically unfit surgery OR lesion surgically unresectable All intrahepatic disease must encompass within study radiation field Extrahepatic disease outside liver allow provide hepatic disease lifelimiting At least 1,000 cc normal liver No clinical ascites No CNS metastases PATIENT CHARACTERISTICS : Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,800/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8 g/dL ( transfusion allow ) Hepatic No active hepatitis No clinically significant liver failure No underlying cirrhosis Renal Not specify Cardiovascular No congestive heart failure require hospitalization within past 6 month No unstable angina pectoris require hospitalization within past 6 month No transmural myocardial infarction within past 6 month Pulmonary No chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 3 year except nonmelanomatous skin cancer carcinoma situ breast , oral cavity , cervix primary liver metastasis No acute bacterial fungal infection require IV antibiotic PRIOR CONCURRENT THERAPY : Chemotherapy At least 4 week since prior chemotherapy No concurrent chemotherapy No anthracyclines within 4 week completion study therapy ( 1 week chemotherapy ) Radiotherapy No prior radiotherapy region study No concurrent intensitymodulated radiotherapy Surgery Prior liver resection ablative therapy allow Other No concurrent warfarin IV heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>liver metastasis</keyword>
</DOC>